Which has preferable valuation and earnings, CPH or CRON?

Cipher Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cipher Pharmaceuticals C$50.94M 8.13 C$11.41M C$1.19 13.70 Cronos Group C$159.54M 8.92 -C$32.78M N/A N/A

Does the media favor CPH or CRON?

In the previous week, Cipher Pharmaceuticals and Cipher Pharmaceuticals both had 1 articles in the media. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cipher Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cronos Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, CPH or THCX?

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cipher Pharmaceuticals C$50.94M 8.13 C$11.41M C$1.19 13.70 Hydropothecary N/A N/A N/A N/A N/A

Cipher Pharmaceuticals (CPH) Competitors

C$16.30 -0.03 (-0.18%)

As of 12:46 PM Eastern

Compare

CPH vs. CRON, DHT.UN, THCX, GUD, and TLRY

Should you buy Cipher Pharmaceuticals stock or one of its competitors? MarketBeat compares Cipher Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cipher Pharmaceuticals include Cronos Group (CRON), DRI Healthcare Trust (DHT.UN), Hydropothecary (THCX), Knight Therapeutics (GUD), and Tilray Brands (TLRY). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Cipher Pharmaceuticals compare to Cronos Group?

Cipher Pharmaceuticals (TSE:CPH) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Cipher Pharmaceuticals has a beta of 1.104631, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Cronos Group has a beta of 1.134248, suggesting that its share price is 13% more volatile than the broader market.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.13	C$11.41M	C$1.19	13.70
Cronos Group	C$159.54M	8.92	-C$32.78M	N/A	N/A

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 4.6% of Cronos Group shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Comparatively, 46.4% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Cipher Pharmaceuticals and Cipher Pharmaceuticals both had 1 articles in the media. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cipher Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cronos Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to Cronos Group's net margin of -1.29%. Cipher Pharmaceuticals' return on equity of 25.69% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Cronos Group	-1.29%	-0.19%	-3.73%

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential upside of 4.29%. Cronos Group has a consensus target price of C$4.75, indicating a potential upside of 24.67%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Cronos Group beats Cipher Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Cipher Pharmaceuticals (TSE:CPH) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential upside of 4.29%. DRI Healthcare Trust has a consensus target price of C$25.50, indicating a potential upside of 49.47%. Given DRI Healthcare Trust's stronger consensus rating and higher probable upside, analysts clearly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cipher Pharmaceuticals has a beta of 1.104631, meaning that its share price is 10% more volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.472401, meaning that its share price is 53% less volatile than the broader market.

Cipher Pharmaceuticals has higher earnings, but lower revenue than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.13	C$11.41M	C$1.19	13.70
DRI Healthcare Trust	C$163.77M	5.73	C$9.73M	-C$0.90	N/A

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of DRI Healthcare Trust shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than DRI Healthcare Trust. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for DRI Healthcare Trust. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled DRI Healthcare Trust'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
DRI Healthcare Trust	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 25.69% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
DRI Healthcare Trust	5.02%	2.06%	4.22%

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 11 of the 15 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Cipher Pharmaceuticals (TSE:CPH) and Hydropothecary (CVE:THCX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.13	C$11.41M	C$1.19	13.70
Hydropothecary	N/A	N/A	N/A	N/A	N/A

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, indicating a potential upside of 4.29%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Hydropothecary. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Hydropothecary. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Hydropothecary'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Hydropothecary	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 25.69% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Hydropothecary	N/A	N/A	N/A

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Cipher Pharmaceuticals beats Hydropothecary on 9 of the 9 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Cipher Pharmaceuticals (TSE:CPH) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.0% of Knight Therapeutics shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Knight Therapeutics. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Knight Therapeutics. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Knight Therapeutics	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to Knight Therapeutics' net margin of 1.10%. Cipher Pharmaceuticals' return on equity of 25.69% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Knight Therapeutics	1.10%	0.73%	0.51%

Cipher Pharmaceuticals has a beta of 1.104631, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.141784, suggesting that its share price is 114% less volatile than the broader market.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.13	C$11.41M	C$1.19	13.70
Knight Therapeutics	C$510.45M	1.78	-C$30.73M	C$0.06	154.50

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, indicating a potential upside of 4.29%. Knight Therapeutics has a consensus target price of C$9.50, indicating a potential upside of 2.48%. Given Cipher Pharmaceuticals' higher probable upside, equities research analysts plainly believe Cipher Pharmaceuticals is more favorable than Knight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Cipher Pharmaceuticals beats Knight Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Cipher Pharmaceuticals (TSE:CPH) and Tilray Brands (TSE:TLRY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.5% of Tilray Brands shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cipher Pharmaceuticals had 1 more articles in the media than Tilray Brands. MarketBeat recorded 1 mentions for Cipher Pharmaceuticals and 0 mentions for Tilray Brands. Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Tilray Brands'average media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Tilray Brands	Neutral

Cipher Pharmaceuticals has a beta of 1.104631, indicating that its share price is 10% more volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.007995, indicating that its share price is 201% more volatile than the broader market.

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential upside of 4.29%. Tilray Brands has a consensus target price of C$13.30, indicating a potential upside of 101.52%. Given Tilray Brands' higher possible upside, analysts plainly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cipher Pharmaceuticals has a net margin of 60.82% compared to Tilray Brands' net margin of -158.75%. Cipher Pharmaceuticals' return on equity of 25.69% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Tilray Brands	-158.75%	-88.06%	-1.41%

Cipher Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.13	C$11.41M	C$1.19	13.70
Tilray Brands	C$858.28M	0.93	-C$183.24M	-C$14.63	N/A

Summary

Cipher Pharmaceuticals beats Tilray Brands on 9 of the 13 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPH vs. The Competition

Export

Metric	Cipher Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$413.87M	C$2.35B	C$6.50B	C$12.25B
Dividend Yield	N/A	2.95%	2.68%	6.19%
P/E Ratio	13.70	4.91	24.67	35.73
Price / Sales	8.13	1,652.64	532.48	10.61
Price / Cash	3.53	10.18	27.92	82.29
Price / Book	3.10	11.00	10.89	4.45
Net Income	C$11.41M	C$20.27B	C$3.56B	C$299.09M
7 Day Performance	0.56%	-0.63%	2.19%	-1.35%
1 Month Performance	-2.74%	-0.84%	0.94%	-1.09%
1 Year Performance	26.36%	13.97%	33.91%	40.84%

Cipher Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPH Cipher Pharmaceuticals	0.6068 of 5 stars	C$16.30 -0.2%	C$17.00 +4.3%	+28.0%	C$413.87M	C$50.94M	13.70	5
CRON Cronos Group	2.1392 of 5 stars	C$3.85 +2.4%	C$4.75 +23.4%	+45.9%	C$1.44B	C$159.54M	N/A	450	News Coverage
DHT.UN DRI Healthcare Trust	1.9556 of 5 stars	C$17.77 -2.2%	C$25.50 +43.5%	+30.5%	C$977.63M	C$163.77M	N/A	N/A	Positive News Dividend Announcement
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
GUD Knight Therapeutics	N/A	C$9.32 +0.1%	C$9.50 +1.9%	+59.1%	C$915.03M	C$510.45M	155.33	725

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, DHT.UN, THCX, GUD, and TLRY

How does Cipher Pharmaceuticals compare to Cronos Group?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Summary

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, DHT.UN, THCX, GUD, and TLRY

How does Cipher Pharmaceuticals compare to Cronos Group?

Which has more volatility and risk, CPH or CRON?

Which has preferable valuation and earnings, CPH or CRON?

Do insiders & institutionals believe in CPH or CRON?

Does the media favor CPH or CRON?

Is CPH or CRON more profitable?

Do analysts recommend CPH or CRON?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Do analysts recommend CPH or DHT.UN?

Which has more risk & volatility, CPH or DHT.UN?

Which has preferable valuation and earnings, CPH or DHT.UN?

Do insiders and institutionals believe in CPH or DHT.UN?

Does the media prefer CPH or DHT.UN?

Is CPH or DHT.UN more profitable?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Which has stronger valuation & earnings, CPH or THCX?

Do analysts recommend CPH or THCX?

Does the media favor CPH or THCX?

Is CPH or THCX more profitable?

Do institutionals & insiders believe in CPH or THCX?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Do insiders and institutionals have more ownership in CPH or GUD?

Does the media prefer CPH or GUD?

Is CPH or GUD more profitable?

Which has more risk and volatility, CPH or GUD?

Which has stronger earnings and valuation, CPH or GUD?

Do analysts rate CPH or GUD?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Do insiders & institutionals believe in CPH or TLRY?

Does the media favor CPH or TLRY?

Which has more risk and volatility, CPH or TLRY?

Do analysts prefer CPH or TLRY?

Is CPH or TLRY more profitable?

Which has preferable earnings & valuation, CPH or TLRY?

Summary

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools